Monday, May 10, 2021 11:13:57 AM
Press Release | 05/06/2021
Xcelerate, Inc. Signs Letter of Intent to Explore Business Relationship with HS Pharmaceuticals
PR Newswire
MAULDIN, S.C., May 6, 2021
MAULDIN, S.C., May 6, 2021 /PRNewswire/ -- Xcelerate, Inc. (OTC pink sheets: XCRT) today announced it has signed a non-binding letter of intent to pursue a business combination with HS Pharmaceuticals, LLC of Greenville, SC. Over the past 14 years HS Pharmaceuticals has developed a platform of novel technologies centered around their patented and patent pending silicate particle research. Their research, in conjunction with leading universities and research facilities, has led to developments in healthcare in areas such as immunotherapy alternatives, topical therapies to combat infection and bacteria as well bone regeneration. For more information visit their website www.hspharma.com.
The LOI provides for XCRT to undertake its due diligence wherein its world-renowned team of clinicians and researchers will review HS Pharmaceuticals' operations, structure, and intellectual property. "During this process, Xcelerate, a rapidly emerging leader in assembling and developing early-stage medical technology, will determine how and in what structure HS Pharmaceuticals research and IP would fit within its business plan. The potential consolidation with HS Pharmaceuticals is further evidence that Xcelerate seeks to continue making headway in finding innovative acquisitions within the patent/engineering world. We remain focused on joining early-stage medical technology companies in a setting of controlled clinical care where these new developments can be trialed, tested and applied," said Xcelerate CEO Michael F. O'Shea.
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
Media contact: Justin Baronoff 561-750-9800; justin@transmediagroup.com.
Cision View original content:http://www.prnewswire.com/news-releases/xcelerate-inc-signs-letter-of-intent-to-explore-business-relationship-with-hs-pharmaceuticals-301286074.html
SOURCE Xcelerate, Inc.
Recent XCRT News
- Form 1-U - Current Report Pursuant to Regulation A • Edgar (US Regulatory) • 05/10/2024 07:01:28 PM
- Form 1-U - Current Report Pursuant to Regulation A • Edgar (US Regulatory) • 05/06/2024 03:55:15 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM